The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.
Identifieur interne : 000983 ( Main/Corpus ); précédent : 000982; suivant : 000984The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.
Auteurs : Teshale Ayele Mega ; Temesgen Mulugeta Feyissa ; Dula Dessalegn Bosho ; Kabaye Kumela Goro ; Getandale Zeleke NegeraSource :
- Canadian respiratory journal [ 1916-7245 ] ; 2020.
English descriptors
- KwdEn :
- Anti-Bacterial Agents (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Enzyme Inhibitors (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Antiviral Agents, Azithromycin, Enzyme Inhibitors, Hydroxychloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
Background
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in an unprecedented public health challenge worldwide. Despite urgent and extensive global efforts, the existing evidence is inconclusive regarding the medications used for the treatment of COVID-19.
Purpose
To generate an up-to-date evidence for the clinical safety and efficacy of hydroxychloroquine (HCQ) with or without azithromycin (AZ) among patients treated for COVID-19.
Conclusion
This meta-analysis and systematic review, which included a limited number of poorly designed studies of patients with COVID-19, revealed HCQ is intolerable, unsafe, and not efficacious. Similarly, HCQ + AZ combination was not different from HCQ alone in curbing mortality and ICU admission.
DOI: 10.1155/2020/4312519
PubMed: 33082891
PubMed Central: PMC7556078
Links to Exploration step
pubmed:33082891Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.</title>
<author><name sortKey="Ayele Mega, Teshale" sort="Ayele Mega, Teshale" uniqKey="Ayele Mega T" first="Teshale" last="Ayele Mega">Teshale Ayele Mega</name>
<affiliation><nlm:affiliation>Deaprtment of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Feyissa, Temesgen Mulugeta" sort="Feyissa, Temesgen Mulugeta" uniqKey="Feyissa T" first="Temesgen Mulugeta" last="Feyissa">Temesgen Mulugeta Feyissa</name>
<affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dessalegn Bosho, Dula" sort="Dessalegn Bosho, Dula" uniqKey="Dessalegn Bosho D" first="Dula" last="Dessalegn Bosho">Dula Dessalegn Bosho</name>
<affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kumela Goro, Kabaye" sort="Kumela Goro, Kabaye" uniqKey="Kumela Goro K" first="Kabaye" last="Kumela Goro">Kabaye Kumela Goro</name>
<affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zeleke Negera, Getandale" sort="Zeleke Negera, Getandale" uniqKey="Zeleke Negera G" first="Getandale" last="Zeleke Negera">Getandale Zeleke Negera</name>
<affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33082891</idno>
<idno type="pmid">33082891</idno>
<idno type="doi">10.1155/2020/4312519</idno>
<idno type="pmc">PMC7556078</idno>
<idno type="wicri:Area/Main/Corpus">000983</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000983</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.</title>
<author><name sortKey="Ayele Mega, Teshale" sort="Ayele Mega, Teshale" uniqKey="Ayele Mega T" first="Teshale" last="Ayele Mega">Teshale Ayele Mega</name>
<affiliation><nlm:affiliation>Deaprtment of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Feyissa, Temesgen Mulugeta" sort="Feyissa, Temesgen Mulugeta" uniqKey="Feyissa T" first="Temesgen Mulugeta" last="Feyissa">Temesgen Mulugeta Feyissa</name>
<affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dessalegn Bosho, Dula" sort="Dessalegn Bosho, Dula" uniqKey="Dessalegn Bosho D" first="Dula" last="Dessalegn Bosho">Dula Dessalegn Bosho</name>
<affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kumela Goro, Kabaye" sort="Kumela Goro, Kabaye" uniqKey="Kumela Goro K" first="Kabaye" last="Kumela Goro">Kabaye Kumela Goro</name>
<affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zeleke Negera, Getandale" sort="Zeleke Negera, Getandale" uniqKey="Zeleke Negera G" first="Getandale" last="Zeleke Negera">Getandale Zeleke Negera</name>
<affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Canadian respiratory journal</title>
<idno type="eISSN">1916-7245</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Enzyme Inhibitors</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>Background</b>
</p>
<p>The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in an unprecedented public health challenge worldwide. Despite urgent and extensive global efforts, the existing evidence is inconclusive regarding the medications used for the treatment of COVID-19.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Purpose</b>
</p>
<p>To generate an up-to-date evidence for the clinical safety and efficacy of hydroxychloroquine (HCQ) with or without azithromycin (AZ) among patients treated for COVID-19. </p>
</div>
<div type="abstract" xml:lang="en"><p><b>Conclusion</b>
</p>
<p>This meta-analysis and systematic review, which included a limited number of poorly designed studies of patients with COVID-19, revealed HCQ is intolerable, unsafe, and not efficacious. Similarly, HCQ + AZ combination was not different from HCQ alone in curbing mortality and ICU admission.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33082891</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1916-7245</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>2020</Volume>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Canadian respiratory journal</Title>
<ISOAbbreviation>Can Respir J</ISOAbbreviation>
</Journal>
<ArticleTitle>The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.</ArticleTitle>
<Pagination><MedlinePgn>4312519</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2020/4312519</ELocationID>
<Abstract><AbstractText Label="Background">The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in an unprecedented public health challenge worldwide. Despite urgent and extensive global efforts, the existing evidence is inconclusive regarding the medications used for the treatment of COVID-19.</AbstractText>
<AbstractText Label="Purpose">To generate an up-to-date evidence for the clinical safety and efficacy of hydroxychloroquine (HCQ) with or without azithromycin (AZ) among patients treated for COVID-19. <i>Data Source</i>
. PubMed, Cochrane CENTRAL, LITCOVID, Web of Science, SCOPUS, BioRxiv, Embase, MedRxiv, and Wiley online library were searched from 2019/12/30 to 2020/05/23. <i>Study Selection</i>
. Three investigators assessed the quality of the studies. <i>Data Extraction</i>
. Data about study characteristics, effect estimates, and the quality of the studies were extracted by two independent reviewers and cross-checked by the third reviewer. <i>Data Synthesis</i>
. The data of 6,782 (HCQ group, 3623; HCQ + AZ group, 1,020; control group, 2139) participants were included. HCQ was compared with standard care for virologic efficacy, disease progression, mortality, and adverse effects. HCQ was also compared with HCQ + AZ for QTc prolongation, admission to the intensive care unit, and mortality. The study found HCQ did not alter the rate of virologic cure (OR = 0.78; 95% CI: 0.39-1.56) and the risk of mortality (OR = 1.26; 95% CI: 0.66-2.39). The pooled prevalence for mortality was 5.8% (95% CI: 0.9%-10.8%). Moreover, HCQ did not impact disease progression (OR = 0.9; 95% CI: 0.36-2.29) but resulted in a higher risk of adverse effects (OR = 2.35; 95% CI: 1.15-4.8). HCQ was also compared against HCQ + AZ, and no difference was observed in QTc prolongation above 500 ms (OR = 1.11; 95% CI: 0.54-2.28), admission to the intensive care unit (OR = 0.92; 95% CI: 0.52-1.63), and mortality (OR = 0.88; 95% CI: 0.55-1.43). However, in the analysis of single-arm studies, about 11.2% (95% CI: 7.0%-15.5%) of patients have developed an absolute increase of QTc greater than 500 ms, and 4.1% (95% CI: 1.1%-7.1%) of patients discontinued their medication.</AbstractText>
<AbstractText Label="Conclusion">This meta-analysis and systematic review, which included a limited number of poorly designed studies of patients with COVID-19, revealed HCQ is intolerable, unsafe, and not efficacious. Similarly, HCQ + AZ combination was not different from HCQ alone in curbing mortality and ICU admission.</AbstractText>
<CopyrightInformation>Copyright © 2020 Teshale Ayele Mega et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayele Mega</LastName>
<ForeName>Teshale</ForeName>
<Initials>T</Initials>
<Identifier Source="ORCID">0000-0003-1619-0104</Identifier>
<AffiliationInfo><Affiliation>Deaprtment of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Feyissa</LastName>
<ForeName>Temesgen Mulugeta</ForeName>
<Initials>TM</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dessalegn Bosho</LastName>
<ForeName>Dula</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kumela Goro</LastName>
<ForeName>Kabaye</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zeleke Negera</LastName>
<ForeName>Getandale</ForeName>
<Initials>G</Initials>
<Identifier Source="ORCID">0000-0002-0178-5888</Identifier>
<AffiliationInfo><Affiliation>Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>10</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Egypt</Country>
<MedlineTA>Can Respir J</MedlineTA>
<NlmUniqueID>9433332</NlmUniqueID>
<ISSNLinking>1198-2241</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>06</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>08</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>09</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>2</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33082891</ArticleId>
<ArticleId IdType="doi">10.1155/2020/4312519</ArticleId>
<ArticleId IdType="pmc">PMC7556078</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Med (N Y). 2020 Jun 5;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Heart Rhythm. 2020 Sep;17(9):1425-1433</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32407884</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2017 Dec;77(18):1935-1966</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29143192</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1844</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2016 Oct 12;355:i4919</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27733354</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Emerg Med. 2020 Jul;38(7):1488-1493</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32336586</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2010 Mar 2;121(8):1047-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20142454</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2020 Jul;157:104872</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32360583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Jun;26(6):808-809</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32488217</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Infect. 2020 Sep;26(9):1276-1277</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32422406</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 21;382(21):e68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32369282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jul;92(7):776-785</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32297988</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Cardiol. 2020 Jun 16;75(23):2992-2993</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330546</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Heart Rhythm. 2020 Sep;17(9):1472-1479</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32438018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Heart Assoc. 2020 Jun 16;9(12):e017144</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32463348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2020 Oct;108(4):791-797</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32324898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32347743</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Toxicol. 2020 Jul;16(3):284-294</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32356252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Sep 1;5(9):1067-1069</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32936266</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab Syndr. 2020 Jul - Aug;14(4):589-596</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32417708</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101738</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32387409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Clin Pharmacol. 2017;12(4):210-222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29473523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chin Med Assoc. 2020 Sep 15;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32947506</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cardiol. 2020 Oct 1;316:280-284</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32439366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>HeartRhythm Case Rep. 2020 Apr 01;6(5):244-248</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32363145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Sep 1;5(9):1036-1041</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32936252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Med. 2020 Mar 31;9(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32244365</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000983 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000983 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:33082891 |texte= The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33082891" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |